article thumbnail

Hansa gets NICE okay for Idefirix in kidney transplant patients

pharmaphorum

Around a third of patients waiting for a kidney transplant are cases as “sensitised” – meaning they have very high antibody levels to human leukocyte antigens (HLAs), which makes it more likely they will reject a donated organ. The post Hansa gets NICE okay for Idefirix in kidney transplant patients appeared first on.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. These antibodies play a crucial role in providing protection by effectively neutralizing the cytotoxic lethal toxin and edema toxin of B. Overall, 66.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A new era in diagnostics: The growing demand for POC testing

Pharmaceutical Technology

While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). The antihistamine treatment is currently being evaluated in larger clinical trials.

article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

article thumbnail

Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials

XTalks

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

article thumbnail

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.

The Pharma Data

” In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants and demonstrated good immune responses compared to the current standard of care. Phase I/II clinical trials to assess the use of the vaccine in paediatrics are planned to begin later this year. About Pneumococcal disease.